At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Venetoclax blocks Bcl-2, a protein that helps cancer cells survive and resist the effects of anti-cancer treatments. By blocking Bcl-2, venetoclax may cause the death of cancer cells or make them more sensitive to other treatments. It is taken orally (by mouth).
- A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders
Full Title Cord Blood Transplantation in Children and Young Adults with Hematologic Malignancies and Non-Malignant Disorders
Purpose
The transplantation of stem cells from umbilical cord blood is a treatment for some blood cancers and non-cancerous blood or metabolic disorders. Patients routinely receive high doses of chemotherapy and sometimes radiation before receiving the stem cells to help make room in the bone marrow for new blood stem cells to grow, prevent the body from rejecting the transplanted cells, and help kill any abnormal blood cells in the body. However, the combination of these treatments can have serious side effects.
Researchers are doing this study to find out whether a combination of the chemotherapy drugs clofarabine, fludarabine, and busulfan (without radiation) is a safe and effective treatment for children and young adults receiving cord blood transplants for blood cancers or non-cancerous blood or metabolic disorders. These three drugs are given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a blood cancer or non-cancerous blood disorder and be candidates for umbilical cord transplantation. Examples of blood cancers include acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), advanced myelodysplasia (MDS), chronic myelogenous leukemia (CML), myeloproliferative disorders, and non-Hodgkin and Hodgkin lymphoma. Examples of non-cancerous disorders include inherited metabolic diseases, Hurler syndrome, Hunter disease, Sly syndrome, alpha-mannosidosis, X-ALD (X-linked adrenoleukodystrophy), osteopetrosis, metachromatic leukodystrophy, globoid cell leukodystrophy, bone marrow failure syndromes, and diseases like HLH (hemophagocytic lymphohistiocytosis) caused by a compromised immune system.
- This study is for patients age 21 and younger.
For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.
Protocol
20-480Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04644016ClinicalTrials.gov
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Doctors routinely use intensity-modulated radiation therapy (IMRT) after surgery to treat squamous cell carcinoma (cancer) of the tongue. IMRT delivers radiation directly to cancer cells from different angles by changing the radiation beam into multiple smaller beams. By targeting the tumor more precisely, IMRT reduces radiation damage to healthy tissue.
-
Researchers want to see if a single radiation therapy dose can limit the growth of colorectal cancer liver metastases. The people in this study have colorectal cancer that has metastasized (spread) to the liver. The treatment is called high-dose stereotactic body radiation therapy (SBRT).
-
Researchers want to see if giving NALIRIFOX chemotherapy with high-dose radiation therapy and capecitabine before surgery helps people with pancreatic cancer. The people in this study have pancreatic cancer that involves major blood vessels but has not spread to other organs. The study includes people with pancreatic cancer that may or may not be removable ("borderline resectable" or "locally advanced").
-
Padeliporfin VTP (vascular targeted photodynamic) therapy uses targeted laser light to destroy cancer cells while causing minimal damage to the tissues around the cancer. In this study, researchers want to learn if padeliporfin VTP therapy is effective and safe for people with low-grade upper urothelial cancers (tumors of the kidney or ureter) that have not spread.
-
Researchers are studying combining RMC-6236 with other anti-cancer drugs in people with advanced digestive cancers (pancreatic, colorectal cancer, and others). The people in this study have either:
-
Researchers are comparing pembrolizumab given after surgery for head and neck cancer with the usual treatment. The usual therapy includes chemotherapy and radiation therapy. The people in this study have head and neck cancer that came back or is a new primary cancer.
-
In this study, researchers are comparing selumetinib plus olaparib to selumetinib alone to treat endometrial or ovarian cancer. People in this study have cancer that came back or keeps growing after treatment. In addition, their cancers have a change (mutation or variant) in a RAS gene.